The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 40 | — | 20.1x | Near average | |
Growth | 46 | — | 5.6% | Near average | |
Quality | 10 | -102.7% | 7.6% | Below average | |
Safety | 21 | 0.2x | 0.4x | Below average | |
Capital Return | 31 | — | 2.19% | Below average | |
Momentum | 56 | — | — | Near average | |
Sentiment | 27 | — | — | Below average |
Acumen Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Acumen Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
ABOS stock has seen notable stability in its price target at $7, with zero dispersion among analysts as the high and low estimates matched. The most significant recent change is the addition of a new analyst within the last 24 hours, bringing the number of analysts covering the stock to two, both adopting the same optimistic price target, reflecting full consensus despite the small sample size.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.